BA
ICPT

BlackRock Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BlackRock Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.1M Buy
10,145
+676
+7% +$80.5K ﹤0.01% 1811
2016
Q3 		$1.56M Buy
9,469
+264
+3% +$41.6K ﹤0.01% 1590
2016
Q2 		$1.31M Buy
9,205
+1,187
+15% +$173K ﹤0.01% 1650
2016
Q1 		$1.03M Sell
8,018
-117,256
-94% -$13.8M ﹤0.01% 1727
2015
Q4 		$18.7M Buy
125,274
+6,461
+5% +$1.09M 0.02% 566
2015
Q3 		$19.7M Sell
118,813
-12,360
-9% -$2.72M 0.02% 529
2015
Q2 		$31.7M Buy
131,173
+10,068
+8% +$2.68M 0.03% 405
2015
Q1 		$34.2M Buy
121,105
+118,978
+5,594% +$25.8M 0.04% 400
2014
Q4 		$332K Hold
2,127
– – ﹤0.01% 2296
2014
Q3 		$503K Buy
2,127
+236
+12% +$60.2K ﹤0.01% 1972
2014
Q2 		$447K Sell
1,891
-9,188
-83% -$2.42M ﹤0.01% 2090
2014
Q1 		$3.65M Buy
11,079
+7,523
+212% +$2.54M ﹤0.01% 1036
2013
Q4 		$243K Buy
3,556
+267
+8% +$15.4K ﹤0.01% 2545
2013
Q3 		$227K Buy
3,289
+447
+16% +$22.1K ﹤0.01% 2469
2013
Q2 		$127K Buy
+2,842
New +$97.1K ﹤0.01% 2745

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BlackRock Advisors's ICPT Position: Q4 2016 in Review

BlackRock Advisors increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 7.1% in Q4 2016, buying an estimated $80.5K and bringing the position to 10,145 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

BlackRock Advisors first reported a position in ICPT in Q2 2013 and has held it in 15 quarters since. The position peaked at $34.2M in Q1 2015. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • BlackRock Advisors held 10,145 shares of Intercept Pharmaceuticals, Inc. worth $1.1M as of Q4 2016.
  • BlackRock Advisors bought 676 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $80.5K.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1811 holding.
  • BlackRock Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Intercept Pharmaceuticals, Inc. position peaked at $34.2M in Q1 2015.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.